TY - JOUR

T1 - Boron neutron capture therapy: Current status and future perspectives

AU - Dymova, Mayya Alexandrovna

AU - Taskaev, Sergey Yurjevich

AU - Richter, Vladimir Alexandrovich

AU - Kuligina, Elena Vladimirovna

N1 - Funding Information: This study was supported by the Russian Science Foundation (project No. 19‐72‐30005) and the Russian State funded budget project (ICBFM SB RAS АААА‐А17‐117020210023‐1). Publisher Copyright: © 2020 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/9/1

Y1 - 2020/9/1

N2 - The development of new accelerators has given a new impetus to the development of new drugs and treatment technologies using boron neutron capture therapy (BNCT). We analyzed the current status and future directions of BNCT for cancer treatment, as well as the main issues related to its introduction. This review highlights the principles of BNCT and the key milestones in its development: new boron delivery drugs and different types of charged particle accelerators are described; several important aspects of BNCT implementation are discussed. BCNT could be used alone or in combination with chemotherapy and radiotherapy, and it is evaluated in light of the outlined issues. For the speedy implementation of BCNT in medical practice, it is necessary to develop more selective boron delivery agents and to generate an epithermal neutron beam with definite characteristics. Pharmacological companies and research laboratories should have access to accelerators for large-scale screening of new, more specific boron delivery agents.

AB - The development of new accelerators has given a new impetus to the development of new drugs and treatment technologies using boron neutron capture therapy (BNCT). We analyzed the current status and future directions of BNCT for cancer treatment, as well as the main issues related to its introduction. This review highlights the principles of BNCT and the key milestones in its development: new boron delivery drugs and different types of charged particle accelerators are described; several important aspects of BNCT implementation are discussed. BCNT could be used alone or in combination with chemotherapy and radiotherapy, and it is evaluated in light of the outlined issues. For the speedy implementation of BCNT in medical practice, it is necessary to develop more selective boron delivery agents and to generate an epithermal neutron beam with definite characteristics. Pharmacological companies and research laboratories should have access to accelerators for large-scale screening of new, more specific boron delivery agents.

KW - boron compounds

KW - Boron neutron capture therapy

KW - cancer

KW - cancer treatment

KW - drug delivery

KW - EPITHERMAL NEUTRON

KW - BNCT

KW - CLINICAL-TRIAL

KW - DNA-DAMAGE

KW - MALIGNANT PLEURAL MESOTHELIOMA

KW - BLOOD-BRAIN-BARRIER

KW - NECK-CANCER

KW - IN-VITRO

KW - RECURRENT HEAD

KW - SQUAMOUS-CELL CARCINOMA

UR - http://www.scopus.com/inward/record.url?scp=85089454654&partnerID=8YFLogxK

U2 - 10.1002/cac2.12089

DO - 10.1002/cac2.12089

M3 - Review article

C2 - 32805063

AN - SCOPUS:85089454654

VL - 40

SP - 406

EP - 421

JO - Cancer Communications

JF - Cancer Communications

SN - 2523-3548

IS - 9

ER -